<DOC>
	<DOCNO>NCT00132496</DOCNO>
	<brief_summary>The primary objective study collect safety information rabeprazole 10 mg 20 mg treatment gastroesophageal reflux disease ( GERD ) child age 12 16 year . The secondary objective assess efficacy rabeprazole improvement symptom GERD explore relationship symptom relief dose receive , base symptom frequency severity , antacid use , quality life ( QOL ) measure .</brief_summary>
	<brief_title>Treatment Gastroesophageal Reflux Disease 12-16 Year Old Patients With Rabeprazole</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>1 . Males female age 12 16 year clinical diagnosis symptomatic GERD suspect endoscopically proven GERD . 2 . Patients ever treat , currently receive proton pump inhibitor ( PPIs ) , histamine receptor ( H2 ) blocker , antacid eligible ( long go PPIs H2 blocker three day prior dose , except cimetidine , must discontinue least seven day prior dose ; exclusion criterion 5 6 ) . Also , patient able go PPI therapy two week end active drug treatment . 3 . Children stable asthma/reactive airway disease stable treatment regimen eligible . 4 . Children stable dos allergy , antiepileptic , antidepressant , attention deficit disorder medicine eligible . 5 . Patients must able willing swallow test drug tablet intact . The ability child swallow intact tablet must confirm site Screening . 6 . The patient willing able give assent participate . 7 . The patient 's parent guardian give write informed consent . 8 . Postpubertal female require abstinent course study . 9 . Clinically insignificant laboratory finding . 1 . Evidence significant hepatic , renal , respiratory , endocrine , immune , infectious , hematologic , neurologic , psychiatric , cardiovascular system abnormality would interfere conduct study , interpretation study result , health patient study . 2 . History primary esophageal motility disorder systemic condition affect esophagus ( eg , scleroderma , esophageal infection ) . 3 . History eosinophilic esophagitis , persistent milk protein allergy , allergic gastroenteropathy . History current presence peptic ulcer ; current presence Helicobacter pylorus . 4 . History definitive acidlowering surgery , previous esophageal surgery , esophageal stricture disallow . History fundoplication feed tube insertion allow . 5 . Treatment full therapeutic dos H2receptor antagonist sucralfate within three day prior dose ( short washout agree Investigator Sponsor ) , except cimetidine , must discontinue least seven day prior dose . 6 . Treatment proton pump inhibitor within three day prior dose ( short washout agree Investigator Sponsor ) . 7 . Inability 2week PPI therapyfree period end active drug treatment . 8 . Pregnancy lactation . 9 . Known suspected drug addiction alcohol abuse and/or positive urine drug screen explain medication list ; occasional alcohol tobacco use exclusion criterion . 10 . Unwilling unable abide requirement study violate prohibition restriction study defined Section 9.4 . 11 . Any condition would make patient , opinion Investigator Sponsor , unsuitable study . 12 . Participation another investigational drug study within one month prior dose . 13 . A history allergy/sensitivity proton pump inhibitor inactive ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>GERD</keyword>
</DOC>